Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -41.48% is 21% above its 4-year average of -52.36%, near the high end of its 4-year range (-119.91%–-20.19%).
4.76% below its 12-month average of -39.59%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -12.64%.
RETURN ON ASSETS (ROA)
-41.48%
RETURN ON ASSETS (ROA) AVG TTM
-39.59%
RETURN ON ASSETS (ROA) AVG 3Y
-35.47%
RETURN ON ASSETS (ROA) AVG 5Y
N/A
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
-4.76%
CURRENT VS 3Y AVG
-16.94%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-26.34%
median of 496 covered companies
CURRENT VS SECTOR MEDIAN
-57.45%
vs the sector median at left
ArriVent BioPharma, Inc.
Market Cap
$1.33B
Return on Assets (ROA)
-41.48%
TTM Avg
-39.59%
3Y Avg
-35.47%
5Y Avg
N/A
Market Cap
$1.34B
Return on Assets (ROA)
-68.96%
TTM Avg
-38.41%
3Y Avg
-33.02%
5Y Avg
-35.57%
Market Cap
$1.36B
Return on Assets (ROA)
-49.10%
TTM Avg
-49.10%
3Y Avg
-49.10%
5Y Avg
-49.10%
Market Cap
$1.39B
Return on Assets (ROA)
-89.60%
TTM Avg
418.97%
3Y Avg
177.41%
5Y Avg
100.38%
Market Cap
$1.40B
Return on Assets (ROA)
-21.52%
TTM Avg
-21.52%
3Y Avg
-21.52%
5Y Avg
-21.52%
Market Cap
$1.24B
Return on Assets (ROA)
-48.35%
TTM Avg
-102.84%
3Y Avg
-97.55%
5Y Avg
-75.48%
Market Cap
$1.43B
Return on Assets (ROA)
-32.81%
TTM Avg
-32.81%
3Y Avg
-32.81%
5Y Avg
-32.81%
Market Cap
$1.22B
Return on Assets (ROA)
-0.46%
TTM Avg
-2.95%
3Y Avg
-4.25%
5Y Avg
-4.39%
Market Cap
$1.21B
Return on Assets (ROA)
5.91%
TTM Avg
1.36%
3Y Avg
-4.42%
5Y Avg
-8.30%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| ArriVent BioPharma, Inc. (AVBP) | $1.33B | -41.48% | -39.59% | -35.47% | N/A |
| Alpha Tau Medical Ltd (DRTS)vs › | $1.34B | -68.96% | -38.41% | -33.02% | -35.57% |
| Kardigan, Inc. (KARD)vs › | $1.36B | -49.10% | -49.10% | -49.10% | -49.10% |
| Inhibrx Biosciences Inc. (INBX)vs › | $1.39B | -89.60% | 418.97% | 177.41% | 100.38% |
| Kailera Therapeutics, Inc. (KLRA)vs › | $1.40B | -21.52% | -21.52% | -21.52% | -21.52% |
| Damora Therapeutics, Inc. (DMRA)vs › | $1.24B | -48.35% | -102.84% | -97.55% | -75.48% |
| Hemab Therapeutics Holdings, Inc. Common Stock (COAG)vs › | $1.43B | -32.81% | -32.81% | -32.81% | -32.81% |
| Innovage Holding Corp. (INNV)vs › | $1.22B | -0.46% | -2.95% | -4.25% | -4.39% |
| Cronos Group Inc. (CRON)vs › | $1.21B | 5.91% | 1.36% | -4.42% | -8.30% |
| Avalyn Pharma Inc. Common Stock (AVLN)vs › | $1.20B | -57.23% | -57.23% | -57.23% | -57.23% |
ROA
-41.5%
ROE
-44.6%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -49.92% |
| 2024-12-31 | -29.27% |
| 2023-12-31 | -42.51% |
| 2022-12-31 | -20.19% |
| 2021-12-31 | -119.91% |
